Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women

Summary Adipose tissue is an active endocrine organ secreting different adipokines such as plasminogen activator inhibitor-1 (PAI-1) and adiponectin, among many others. In this study, we investigated the association between PAI-1 activity and serum adiponectin levels in a group of 444 overweight and obese women and assessed the interrelationship with visceral adipose tissue (VAT; CT-scan L4-L5), insulin resistance (HOMA-IR), HDL cholesterol (HDL-chol) and inflammation (hs-CRP). PAI-1 was inversely related to adiponectin (r=-0.25, p<0.001; adjusted for age and BMI).After adjustment for age, VAT, HOMA-IR and hs-CRP, the relationship remained significant (r=-0.15; p=0.001), but disappeared after additional adjustment for HDL-chol (r=-0.09; p=0.067). Subjects were divided in two groups according to the median levels of adiponectin or PAI-1 levels. PAI-1 activity (19.1±11.4 vs. 15.8±8.6 AU/ml; p=0.003) and adiponectin levels (9.8±4.6 vs. 8.4±4.0 μg/ml; p<0.001) were significantly higher in the low adiponectin/PAI-1 groups. The difference in PAI-1 remained significant after adjustment for age and BMI (p=0.001), became borderline significant after adjustment for age and VAT (p=0.052), and disappeared after adjustment for age and HOMA-IR (p=0.116) or age and HDL-chol (p=0.443).The difference in adiponectin levels remained significant after adjustment for age, VAT, HOMA-IR and hs-CRP (p=0.006), but disappeared after additional adjustment for HDL-chol (p=0.089). Further analyses suggest a contribution of HOMA-IR and/or HDL-chol in the relationship between PAI-1 and adiponectin. HDL-chol was found to be the only factor independently determining both factors. In conclusion, in overweight and obese women, PAI-1 activity was inversely related to serum adiponectin, independent of visceral adipose tissue.

[1]  A. Pfeiffer,et al.  Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women , 2005, International Journal of Obesity.

[2]  C. Behre,et al.  The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. , 2005, Metabolism: clinical and experimental.

[3]  L. V. Van Gaal,et al.  Visceral fat as a determinant of fibrinolysis and hemostasis. , 2005, Seminars in vascular medicine.

[4]  C. Mantzoros,et al.  Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. , 2004, Diabetes care.

[5]  J. Małyszko,et al.  Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  K. Choi,et al.  Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans , 2004, Clinical endocrinology.

[7]  T. Funahashi,et al.  Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. , 2004, Diabetes care.

[8]  T. Funahashi,et al.  Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina , 2004, Thrombosis and Haemostasis.

[9]  O. McGuinness,et al.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. , 2004, Diabetes.

[10]  B. Fagerberg,et al.  Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. , 2003, Metabolism: clinical and experimental.

[11]  S. B. Pedersen,et al.  Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. , 2003, American journal of physiology. Endocrinology and metabolism.

[12]  B. Nicklas,et al.  Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. , 2003, Diabetes care.

[13]  S. Yusuf,et al.  Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease , 2003, Circulation.

[14]  T. Funahashi,et al.  Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. , 2003, Diabetes.

[15]  M. Cnop,et al.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex , 2003, Diabetologia.

[16]  NoriyukiOuchi,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003 .

[17]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[18]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[19]  L. V. Van Gaal,et al.  Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[20]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[21]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[22]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[23]  B. Fagerberg,et al.  Insulin Sensitivity and Hemostatic Factors in Clinically Healthy 58-year-old Men , 2000, Thrombosis and Haemostasis.

[24]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[25]  H. Hauner,et al.  Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[28]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[29]  B. Sobel,et al.  TNF- a and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes , 1999 .

[30]  P. Morange,et al.  Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.

[31]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[32]  J. Seidell,et al.  Techniques for the measurement of visceral fat: a practical guide. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[33]  P. Deurenberg,et al.  Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry. , 1989, The American journal of clinical nutrition.

[34]  H C Lukaski,et al.  Assessment of fat-free mass using bioelectrical impedance measurements of the human body. , 1985, The American journal of clinical nutrition.